Skip to content

Impact of Adipose Tissue in COVID-19

Impact of Adipose Tissue in COVID-19 : From Pathophysiology to Therapeutic Perspectives

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04639440
Acronym
COVIFAT
Enrollment
60
Registered
2020-11-20
Start date
2020-11-23
Completion date
2021-11-23
Last updated
2020-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Adipose tissue, Covid19, SARS-CoV2

Brief summary

Overweight or obese patients are particularly exposed to severe forms of COVID-19. Few data suggest that adipose tissue infected with SARS-CoV-2 could be involved in the onset of the cytokine storm seen in severe forms of COVID-19. The aim of this study is to determine the pathogenesis of SARS-CoV-2-infection of adipose tissue. In particular the investigators will study how this virus enters the adipocyte and how it modulates metabolism and inflammation in the adipose tissue. From these data, the investigators hope to determine at the adipose tissue level, original therapeutic targets to modulate the effects of SARS-CoV-2 at the systemic level.

Interventions

OTHERAdipose tissue

Adipose tissue sampling

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age greater than or equal to 18 years * All patients who are obese or overweight (\> 25 kg/m2) or non-obese (\< or = 25 kg/m2) operated for abdominal vascular surgery * Beneficiary or entitled to a social security scheme (except AME)

Exclusion criteria

* Pregnant or breastfeeding woman * Patient refusal * Patient deprived of liberty or subject to a legal protection measure (guardianship, curatorship)

Design outcomes

Primary

MeasureTime frameDescription
Comparison of the expression of ACE2 and TMPRSS2 in the subcutaneous and visceral adipose tissue of obese patients. Determination of cells expressing ACE2 and TMPRSS2 in whole human adipose tissue.12 monthsAnalysis of the expression of mRNA and ACE2 and TMPRSS2 proteins in the subcutaneous and visceral adipose tissue of normal weight and obese patients

Secondary

MeasureTime frameDescription
Demonstration of entry and replication of SARS-CoV-2 in human adipose tissue12 monthsInfection of human adipocytes in lean and obese subjects by SARS-CoV-2
Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.12 monthsAssessment of the expression and secretion of inflammatory cytokines (TNF-α, IL-1 , IL-4 , IL-6 , IL-7 , IL-10 , IL-12 , IL-13 , IL-18 ¸ IL-23, INF-α, INF-β) after infection with SARS-CoV-2 of adipose tissue / adipocytes of thin and obese subjects. Evaluation of SARS-CoV-2 infection on the lipolysis of adipose tissue / adipocytes in thin and obese subjects.
Effect of SARS-CoV-2 infection of adipose tissue / adipocytes from thin and obese subjects on endoplasmic reticulum (ER) homeostasis.12 monthsStudy whether infection with SARS-CoV-2 activates the RE stress pathways in adipose tissue
Target endoplasmic reticulum stress to reduce spread of SARS-CoV-2 from adipose tissue12 monthsUse of RE stress inhibitors on adipocytes infected with SARS-CoV-2 and assess their effect on the maturation of the virus in infected cells.

Countries

France

Contacts

Primary ContactOlivier BOURRON, Dr
olivier.bourron@aphp.fr0142178118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026